Jupiter Neurosciences Executes 1-for-75 Reverse Stock Split to Regain Nasdaq Compliance

• Jupiter Neurosciences executed a 1-for-75 reverse stock split, reducing outstanding shares from 57.8 million to approximately 770,081 to satisfy Nasdaq listing requirements.
• The split-adjusted trading of Jupiter Neurosciences common stock began on August 7, 2026, under the ticker JUNS with a new CUSIP number.
• The company faces severe liquidity constraints and negative book value, though recent capital raises have temporarily improved its cash reserves.
• Jupiter Neurosciences continues to advance its clinical pipeline, including JOTROL for Parkinson's disease and the newly acquired ALA-002 for PTSD.
• The stock has traded as low as $0.07 prior to the split, highlighting the urgency of the corporate restructuring.

Jupiter Neurosciences, Inc. (NASDAQ: JUNS) has officially completed a 1-for-75 reverse stock split of its common stock, a strategic move designed to regain compliance with The Nasdaq Capital Market's minimum bid price requirement. This corporate action became effective after the market closed on August 6, 2026, with split-adjusted trading commencing on August 7, 2026. The restructuring significantly alters the capital structure of the clinical-stage biopharmaceutical company, reducing the number of outstanding common shares from approximately 57,756,143 to about 770,081. The transaction was ratified by stockholders at the annual meeting held on July 22, 2026, and is intended to increase the per-share trading price to meet exchange listing standards. Trading on a split-adjusted basis will proceed under the existing ticker symbol JUNS, accompanied by a new CUSIP number to facilitate the administrative transition. No fractional shares will be issued to shareholders as a result of this consolidation. Instead, holders of fractional shares will receive cash payments calculated based on the closing sales price of the stock on August 6, 2026. This adjustment applies proportionally to the exercise and conversion prices of outstanding stock options and convertible securities, as well as share limits under stock incentive plans. Shareholders holding shares electronically or through brokers will have their positions automatically adjusted without requiring any action. Physical certificate holders will receive instructions from the transfer agent, Equiniti Trust Company, LLC, to exchange certificates or receive cash for fractional equivalents. The total authorized number of shares remains unchanged following the split, preserving the existing equity framework while modifying the per-share valuation metrics.

What Are the Financial Implications of the Reverse Split?

The reverse stock split is a direct response to the company's ongoing valuation challenges and its need to maintain its listing on the Nasdaq exchange. Prior to the split, Jupiter Neurosciences' stock had traded between $0.08 and $1.84 over the past year, with the share price hovering near $0.07. This low valuation posed a risk of non-compliance with Nasdaq's minimum bid price rule, which requires listed companies to maintain a minimum stock price to avoid delisting. The consolidation of shares aims to stabilize the stock price and improve the per-share valuation profile, thereby reducing the immediate risk of delisting. However, the fundamental financial health of the company remains a primary concern for investors. Jupiter Neurosciences exhibits a financially distressed profile relative to industry standards, characterized by a current ratio of 0.507, which is significantly below the industry median of 4.97. This indicates difficulty in covering short-term obligations with current assets. Furthermore, the company operates with a negative book value per share of -0.077, contrasting with the industry positive average of 6.18. These metrics reflect substantial accumulated losses and a high-risk profile typical of pre-revenue or early-stage biotech entities. Despite these challenges, recent balance sheet trends reveal a strategic shift in capital structure. Between late 2024 and early 2025, the company reported a dramatic surge in cash and equivalents, growing to approximately $3.77 million by December 2024. Concurrently, total debt was reduced by over 65% to roughly $0.07 million, and total liabilities decreased significantly. This influx of cash was partly driven by a recent $2.0 million registered direct offering, which was intended to extend the company's cash runway and finance its Parkinson’s disease program. However, projections for late 2025 and 2026 indicate a return to negative equity, driven by continued accumulated deficits in retained earnings. The company's beta of 0.67 suggests lower volatility than the broader market, but the fundamental metrics point to a high-risk entity heavily reliant on capital raises or debt restructuring to maintain operations.

How Does the Clinical Pipeline Influence Future Prospects?

Jupiter Neurosciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neurological and neurodegenerative disorders. The company's pipeline is central to its long-term viability and investor interest. Its present lead program, JOTROL, is a proprietary, enhanced-bioavailability resveratrol formulation currently in a Phase IIa clinical trial for Parkinson’s disease. JOTROL represents a significant investment for the company, as evidenced by the recent capital raise specifically allocated to finance this program. In addition to JOTROL, Jupiter Neurosciences has expanded its pipeline through the acquisition of exclusive U.S. rights to ALA-002, a next-generation, patented psychedelic novel chemical entity (NCE) licensed from PharmAla Biotech. ALA-002 is in clinical development for the treatment of treatment-resistant post-traumatic stress disorder (PTSD) and anxiety. The compound is engineered to improve cardiovascular safety while preserving the therapeutic properties of MDMA-assisted psychotherapy. This acquisition is particularly relevant given the evolving regulatory landscape for psychedelic therapies in the United States. Jupiter Neurosciences also commercializes Nugevia, a consumer longevity supplement, which provides a source of revenue and diversification. The board of directors has recently appointed new members to advance the clinical pipeline and navigate the complexities of regulatory approvals. The combination of JOTROL and ALA-002 positions Jupiter Neurosciences at the intersection of traditional neurology and emerging psychedelic medicine. However, the success of these programs is contingent upon favorable clinical trial results and regulatory approvals, both of which carry inherent risks. The company's financial distress and negative book value underscore the importance of these clinical milestones in determining the future value of the equity. Investors must weigh the potential upside of a successful clinical pipeline against the immediate liquidity constraints and structural risks highlighted by the reverse stock split.